NIH Research Project Cooperative Agreement (U01)
Funds Research Project - Cooperative Agreements, NIH's U01 mechanism.
The National Institutes of Health uses the Research Project - Cooperative Agreements (U01) to support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.
NIH files the mechanism under Research and Development.
Each announcement under U01 sets its own deadline, budget and eligibility. NIH …
Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.
Funds genomic work in animals on what makes addiction start, escalate, persist and relapse — any kind of genetic variant.
Funds the renewal of a neurology clinical trial the institute already supports, where finishing it needs more time and resources.
Funds the first human trials of a novel-mechanism psychiatric drug or a novel neuromodulatory device, with milestones gating each step.
Funds research using a screening trial's biorepository — serial blood samples collected before diagnosis, with decades of matched participant data.
Funds research into how preanalytical handling of biopsies and other biospecimens distorts biomarker results used in clinical assays.
Funds IND-enabling studies and planning that take a gene-based therapy for an ultra-rare neurological or neuromuscular disorder toward its first human trial.
Funds a clinical trial for a communication disorder that NIH runs jointly with the investigator, when the trial meets a high-oversight or high-risk bar.
Funds one investigator's discovery-to-proof-of-concept project on a new drug, ligand or neurostimulation device for a mental or substance use disorder.
Funds a translational research project run jointly with NIH's own intramural investigators at the Clinical Center, up to $500,000.
Funds rigorous preclinical validation and early drug discovery against novel Alzheimer's and related-dementia targets, before human trials.
Funds a research project that plugs into NCI's Metastasis Research Network of systems-level cancer centers, up to $500,000.
Funds research testing causal links between everyday human behaviors and oral-systemic health outcomes in people with chronic conditions.
Funds prospective observational studies or biomarker-validation studies that need new data or biospecimen collection, through a cooperative agreement.
Funds running an investigator-initiated, milestone-driven clinical trial that needs closer NIH oversight, including any mechanistic sub-studies.
Funds hypothesis-based research using cancer epidemiology cohorts, including cohort infrastructure, follow-up, and shared data and biospecimens.
Funds a research project run jointly with an investigator who already works inside NIH's own labs and clinics.
Funds early drug candidates for Alzheimer's disease, from lab bench through the first human safety trial.
Funds a five-award network running canine cancer immunotherapy trials whose results are meant to translate directly into human cancer treatment.
Funds early-stage development of new cancer-research software tools, from first prototype to their first real users.
Funds high-risk clinical trials of new ways to see inside the living human inner ear. A trial is compulsory, and NIH stays in the room.
Funds a single hub that coordinates data, evaluation and operations for a consortium of community-based oral health research projects.
Funds continuing the national registry that tracks outcomes from clinical trials of islet transplants for diabetes.
Funds research into why cardiovascular disease develops in people with type 1 diabetes, through an open-competition consortium.
Funds a clinical centre inside a consortium testing how to use anti-obesity medication in children without harming their growth or mental health.
Funds a single milestone-driven project combining multiple existing Type 1 diabetes datasets with multimodal AI models.
Funds the one centre that coordinates a rare-disease genomics programme and gets its protocols, data and tools out to everybody else.
Funds the centre that turns new molecular methods for rare-disease diagnosis into standards, best practices and a benchmarking dataset.
Funds a genuinely new experimental or computational approach to finding the cause of a rare genetic disorder, where the current state of the art falls short.
Funds research using ancient human DNA data to understand the diseases and traits people carry today.
Funds next-generation sensors and bioelectronic devices that record behaviour in step with brain recordings, to build models of how the two connect.
Funds research using data from expanded access to investigational drugs for people with ALS who are not eligible for any ongoing trial.
Funds moving a genomic or biologic therapy candidate for Alzheimer's-related dementias from lab optimisation through to first human testing.
Funds technology anywhere in the connectomics pipeline — collection, reconstruction, analysis, dissemination — to make brain wiring diagrams faster and cheaper.
Funds the design and early validation of frameworks — guidelines, protocols and standard procedures — for building and deploying multimodal medical AI reliably.